PHILADELPHIA, May 7, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended March 31, 2010. The net loss (including non-cash expenses) for the fiscal quarter was approximately $4,044,000 or $0.03 per share compared to a loss of approximately $3,087,000 or $0.04 per share for the same period in 2009. Increased research and development costs were associated with the effort towards launch of Alferon® N Phase II tests; activity preparatory for new clinical trials of Alferon® LDO and Ampligen®, both experimental therapeutics, along with an increase in overall general and administrative costs.
